Search PubMed⌕ Search

Biomedical subjects

L Inverardi

Publications and source records attributed to L Inverardi.

78 records · Page 5Linked to original sources
PubMedDate not supplied

Signal requirements in the step-wise functional maturation of cytotoxic T lymphocytes.

The generation of effector cytotoxic T lymphocytes from resting precursors proceeds through a series of steps in a pathway that, in aggregate, involves both proliferation and development of cytotoxicity. To understand the relationship of the various signals (mitogens and/or lymphokines) that bring about progress along this pathway, it is desirable to define a series of 'minimal signals', each of which stimulates the cell to proceed to a further stage in this process of differentiation. Stimulation of lymphocytes with two different monoclonal antibodies directed against the CD2 surface molecule induces a proliferative response; we report here that both CD4+ and CD8+ cells proliferate in response to such a stimulus but do not develop cytotoxicity. Addition of recombinant gamma-interferon (rIFN-gamma) or recombinant IL-2 (rIL-2) to the activated cells leads to acquisition of cytotoxic status by the CD8+ cells but not the CD4+ cells. The availability, in addition to precursors and effectors, of an apparently intermediate stage in the form of proliferating CD8+ cells that are non-cytotoxic should facilitate both cellular and molecular studies of this maturation pathway; the differences between CD4+ and CD8+ cells in development of cytotoxicity under these experimental conditions is a valuable model for understanding differentiation of T lymphocytes.

Cells, Cultured↗
PubMedDate not supplied

Islet cell transplantation: in vivo and in vitro functional assessment of nonhuman primate pancreatic islets.

Transplantation of pancreatic islets of Langerhans as a therapeutic approach for treatment of type I diabetes offers an alternative to subcutaneous insulin injections. Normalization of blood glucose levels by transplanted islets may prevent the development of diabetes-related complications. Problems related to rejection, recurrence of autoimmunity, and local inflammation upon transplantation of islets into the liver need to be solved before the implementation of islet cell transplantation can be viewed as a justifiable procedure in a large cohort of patients. Islet cell isolation has been quite successful in small animals, but the translation of this approach to nonhuman primates has been less rewarding. One of the main problems encountered in nonhuman primate models is the difficulty of isolating an adequate number of functional islets for transplantation. The aim of the present study was to develop a method for isolating a sufficient number of viable islets from nonhuman primates to allow for reversal of diabetes. By implementing minor modifications in the automated method for human islet isolation we were able to obtain viable, functional islets that responded normally to glucose stimulation in vitro. These islets were also able to reverse diabetes in immunocompromised nude mice, rendered diabetic by streptozotocin. This method of islet cell isolation has enabled us to proceed with protocols of allogeneic islet cell transplantation in preclinical, nonhuman primate models.

Animals↗
PubMedDate not supplied

Current indications and limits of pancreatic islet transplantation in diabetic nephropathy.

Insulin-dependent diabetes mellitus (IDDM) is a disease caused by a progressive autoimmune destruction of the insulin-producing beta-cells within the pancreas. A major task of diabetes research consists in developing new forms of treatment to delay or prevent the development of the chronic complications associated with the disease. Islet transplantation could become an attractive alternative to whole organ transplantation, since it is a simpler and safer procedure. However, the requirement for long-term immunosuppression has limited the indication of islet transplantation to patients receiving a simultaneous kidney transplant or already bearing one. While the majority of recipients of islet allografts did not become insulin independent, the field has witnessed significant progress and the long-term results in patients with even partial graft function are comparable or better than those achievable with intensive insulin therapy. Recent trials of donor bone marrow infusions combined with solid organ transplants are in progress to determine whether donor-specific tolerance can be achieved with the potential to expand the future indications of islet transplantation in diabetes.

Bone Marrow Transplantation↗